Agilent Technologies Inc. and Applied Spectral Imaging (ASI) Inc. have entered into a marketing agreement for ASI’s GenASIs imaging platforms and Agilent’s fluorescence in situ hybridization (FISH) products.

“Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers,” said Herman Verrelst, vice president and general manager of Agilent’s genomics solutions and clinical applications divisions.

The agreement includes the marketing of Agilent’s Dako Omnis instrument for automated FISH sample processing.

ASI is a developer of imaging solutions for fluorescent, bright-field and spectral image acquisition in karyotyping, FISH and other pathology tests. Agilent provides instruments for the life sciences, diagnostics and applied chemical markets.